Every 8-K that Cartesian Therapeutics, Inc. (RNAC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RNAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNAC filings page.
Cartesian Therapeutics, Inc. reported results for the quarter ended June 30, 2026, while advancing multiple clinical programs for its lead CAR-T candidate Descartes-08 in autoimmune diseases. The Phase 3 AURORA trial in generalized myasthenia gravis is enrolling about 100 patients, with top-line data expected in 1Q27 and a planned BLA filing in mid-2027.
The company is also running the Phase 2 TRITON trial in myositis, with subset data expected in 1H27 to guide a potential pivotal trial, and the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis and other autoimmune diseases, with data expected in 1H27. A new strategic licensing agreement with WestGene supports an in vivo CAR-T platform; a Phase 1 MG trial using targeted lipid nanoparticles is expected to start in 2H26, with in-human data in 1H27.
Liquidity is supported by approximately $149.3 million in cash, cash equivalents and restricted cash as of June 30, 2026 and a credit facility with K2 HealthVentures providing up to $150 million in non-dilutive financing, including an initial $50 million term loan funded in May 2026. The company expects these resources to fund planned operations into 2028. For the quarter, net income was $15.8 million, or $0.47 basic net income per share, with research and development expenses of $20.4 million and general and administrative expenses of $8.7 million.
Cartesian Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. A total of 24,151,536 common shares were represented, equal to approximately 82.42% of shares outstanding as of the April 14, 2026 record date, indicating strong turnout.
Stockholders elected three Class I directors to serve until the 2029 Annual Meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Cartesian Therapeutics entered a strategic licensing agreement with WestGene Biopharma to develop novel in vivo CAR-T therapies for autoimmune diseases. The collaboration combines Cartesian’s mRNA payload from Descartes-08 with WestGene’s targeted lipid nanoparticle platform.
WestGene’s in vivo mRNA CAR-T platform has early clinical data showing favorable safety, including repeated dosing of up to 14 infusions in a single patient with only one Grade 1 cytokine release syndrome event reported. The partners plan a Phase 1 dose-escalation study in generalized myasthenia gravis using mRNA from Descartes-08 delivered via WestGene’s nanoparticles, with trial initiation expected in the second half of 2026 and first clinical data expected in the first half of 2027.
Cartesian Therapeutics entered a senior secured Loan and Security Agreement providing up to $150.0 million in term loans from K2 HealthVentures, with an initial $50.0 million tranche funded and additional tranches tied to clinical, approval and sales milestones or lender discretion.
The debt matures on June 1, 2030, bears interest at the greater of 8.95% or the prime rate plus 2.20%, and includes minimum cash and future revenue covenants as the company advances Descartes-08 through late-stage trials.
Lenders may convert up to $15.0 million of principal into common stock at $8.2526 per share or qualifying financing prices, subject to ownership caps. The company expects the initial funding to extend its cash runway into 2028 while it targets key data readouts and a planned BLA filing in 2027. Chief Medical Officer Milos Miljkovic, M.D., is resigning effective May 31, 2026, with severance consistent with his employment agreement.
Cartesian Therapeutics reported first quarter 2026 results and updated progress on its Descartes-08 cell therapy pipeline. Cash, cash equivalents and restricted cash were $120.4 million as of March 31, 2026, which the company expects will fund planned operations into mid-2027, including completion of the ongoing Phase 3 AURORA trial in myasthenia gravis.
For the quarter, total revenues were $78 thousand versus $1.1 million a year earlier, while research and development expenses rose to $19.5 million from $14.7 million, and general and administrative expenses declined to $7.1 million from $8.3 million. Net loss widened to $39.2 million, or $1.46 per basic share, compared with $17.7 million, or $0.68 per basic share, in the prior-year period.
The company highlighted ongoing enrollment in the randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody–positive myasthenia gravis, initiation of the Phase 2 TRITON trial in multi-refractory myositis, and enrollment of multiple patients in the pediatric Phase 1/2 HELIOS trial in juvenile dermatomyositis. Descartes-08 is an autologous BCMA-targeting CAR-T designed for outpatient administration without preconditioning chemotherapy and has received multiple U.S. FDA designations, including Orphan Drug and Regenerative Medicine Advanced Therapy designations in myasthenia gravis and Rare Pediatric Disease designation in juvenile dermatomyositis.
Cartesian Therapeutics, Inc. reported that board member Murat Kalayoglu, M.D., Ph.D. has informed the company he will resign from its Board of Directors, effective March 31, 2026, to pursue other opportunities.
He currently serves as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee, and will cease serving on these committees in connection with his resignation. The company states that his decision was not due to any disagreement with the company regarding its operations, policies, or practices and expresses appreciation for his service since 2023.
Cartesian Therapeutics, Inc. reported full year 2025 results and a business update centered on its Descartes-08 cell therapy pipeline. The company ended December 31, 2025 with approximately $126.9 million in cash, cash equivalents and restricted cash, which it expects to fund planned operations into mid-2027, including completion of the Phase 3 AURORA trial.
Total 2025 revenue was $2.8 million, down from $38.9 million in 2024, reflecting much lower collaboration and license revenue. Research and development expenses rose to $58.0 million and general and administrative expenses to $31.5 million. An impairment charge of $56.7 million contributed to a larger net loss of $130.3 million, or $5.02 per basic share, compared with a $77.4 million loss in 2024.
Clinically, enrollment is progressing in the Phase 3 AURORA trial in myasthenia gravis, which plans to enroll about 100 patients and was highlighted by Nature Medicine as a trial to watch in 2026. A Phase 2 TRITON trial in myositis is expected to start in the first half of 2026, while the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis is actively enrolling. Descartes-08 has received multiple U.S. FDA designations, and recent Nature Medicine publications described its mechanism of action and 12‑month response data. Leadership changes included adding cell therapy veteran Adrian Bot, M.D., Ph.D., to the board and appointing CEO Carsten Brunn, Ph.D., as chairman.
Cartesian Therapeutics, Inc. filed a current report to furnish new investor materials. The company is making available a corporate slide presentation it uses at industry and investor conferences, attached as Exhibit 99.1, which provides updates and summaries of its business.
The company also issued a press release on January 9, 2026 highlighting recent progress and outlining its 2026 outlook, attached as Exhibit 99.2. These materials are furnished under Regulation FD, not deemed “filed” for liability purposes, and are not incorporated into other securities law filings unless specifically referenced.
Cartesian Therapeutics, Inc. reported that its Board appointed Adrian Bot, M.D., Ph.D. as a Class II director, serving until the 2027 annual meeting, and initially joining the Science and Technology Committee. Dr. Bot is a veteran biopharma R&D executive with extensive experience in immune, cell and gene therapies, including prior senior roles at Kite Pharma and Capstan Therapeutics.
As compensation, he will receive annual cash retainers of $40,000 for Board service and $7,500 for committee service, an option to purchase 17,200 shares at an exercise price of $8.29 per share, and 5,800 restricted stock units, all vesting over three years subject to continued service. The Board also adopted an updated Code of Business Conduct and Ethics applying to all directors, officers and employees, which enhances guidance on protection and use of company assets and information, including bring-your-own-device practices, and replaces the prior code without any waivers.
Cartesian Therapeutics (RNAC) reported initial Phase 2 data for Descartes-08 in systemic lupus erythematosus and outlined plans to expand the program into myositis. In the open-label SLE study, 100% of participants who reached Month 3 follow-up (n=3) achieved LLDAS, with disease remission (DORIS) in two of three. Safety observations noted outpatient administration without preconditioning, mostly mild adverse events, and no CRS or ICANS.
Correlative biomarkers showed a statistically significant (p<0.01) decline in proinflammatory cytokines (IL7, IL10, CCL20, ST1A1) and decreased plasmacytoid dendritic cells, supporting expansion into myositis. The planned randomized, double-blind, placebo-controlled myositis Phase 2 will enroll up to 50 patients, use six weekly outpatient infusions, assess a Week 24 primary endpoint, and include an interim analysis after ten patients reach the endpoint. An IND is planned by the end of 2025, with trial start targeted for the first half of 2026. The company will pause further SLE work on Descartes-08 and development of Descartes-15 to prioritize Descartes-08 in myasthenia gravis (Phase 3) and myositis.
Cartesian Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1 to a Form 8-K.
The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated. The filing lists the company’s common stock trading on The Nasdaq Stock Market LLC under the symbol RNAC.
Cartesian Therapeutics (RNAC) announced board leadership changes and a bylaws update. On October 29, 2025, Carrie S. Cox resigned from the Board, effective immediately, following her appointment as Executive Chair of another public company. The company stated her resignation was not the result of a disagreement regarding operations, policies, or practices.
The Board appointed Carsten Brunn, Ph.D., as Chairman; named Patrick Zenner, M.B.A., as Lead Independent Director; and appointed Kemal Malik, M.B.B.S., as Chair of the Compensation Committee. Dr. Brunn will not receive additional pay for serving as Chairman, while Mr. Zenner and Dr. Malik will be compensated per the Non-Employee Director Compensation Program.
Also on October 29, 2025, the Board approved amended and restated bylaws to include references to the Lead Independent Director role. On October 30, 2025, the company furnished a press release announcing Dr. Brunn’s appointment.
Cartesian Therapeutics (RNAC) eliminated its Chief Scientific Officer role and provided a termination without cause notice to Christopher Jewell, Ph.D., effective November 14, 2025. The company and Dr. Jewell subsequently entered into a separation agreement on October 20, 2025.
Under the agreement, Dr. Jewell released claims through November 14, 2025 in exchange for severance benefits defined in his March 26, 2024 employment agreement, including 12 months of salary and eligibility for a pro‑rated bonus. The separation agreement will be filed with the company’s Annual Report on Form 10‑K for the year ending December 31, 2025.
Cartesian Therapeutics, Inc. reported that its Board of Directors appointed June Seymour as Chief Accounting Officer, effective October 27, 2025. She brings over 20 years of financial leadership in life sciences, including senior finance roles at DNAnexus, Neogene Therapeutics, Autolus and earlier experience at Ernst & Young.
Under her employment agreement, Ms. Seymour will receive an annual base salary of $385,000 and will be eligible for an annual performance bonus targeted at 35% of base salary, prorated for 2025. If her employment is terminated without cause or she resigns for good reason, she may receive six months of salary continuation, a pro-rated bonus and up to six months of COBRA premium payments, subject to customary release and restrictive covenants.
Ms. Seymour will also receive a $80,000 sign-on bonus and an option to purchase 50,000 shares of common stock at the closing price on the October 27, 2025 grant date. The option vests over four years, with 25% after 12 months and the remainder in three equal annual installments. She is subject to non-compete and non-solicitation covenants, and has signed the company’s standard executive indemnification agreement. The company’s Chief Financial Officer, Blaine Davis, remains the principal financial and principal accounting officer.